ranolazine has been researched along with Coronary Disease in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, B; Clegg, S; Mondragon, J; Sheldon, M | 1 |
| Anderson, RD; Bairey Merz, CN; Berman, DS; Brown, GH; Cook-Wiens, G; Handberg, EM; Mehta, PK; Minissian, MB; Pepine, CJ; Petersen, JW; Rogatko, A; Shaw, LJ; Shufelt, CL; Shuster, JJ; Thomson, LE; Wei, J | 1 |
| Battaglia, D; Caminiti, G; Fossati, C; Massaro, R; Rosano, G; Volterrani, M | 1 |
| Carbajal, EV; Deedwania, PC | 1 |
| Boden, WE; Friedewald, VE; Roberts, WC; Stone, GW; Yancy, CW | 1 |
| Custodis, F; Laufs, U | 1 |
| Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH | 1 |
| Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Melloni, C; Newby, LK | 1 |
| Marazzi, G; Rosano, GM; Volterrani, M | 1 |
| Iliceto, S; Marangelli, V; Rizzon, P | 1 |
| Bagger, JP; Bøtker, HE; Nielsen, TT; Thomassen, A | 1 |
| Blackburn, B; Thiemermann, C; Zacharowski, K | 1 |
| SoRelle, R | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Louis, AA; Manousos, IR | 1 |
| Dasgupta, P; Hughes, LO; Jain, D; Lahiri, A; Raftery, EB | 1 |
| Allely, MC; Alps, BJ | 1 |
5 review(s) available for ranolazine and Coronary Disease
| Article | Year |
|---|---|
Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Ivabradine; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2011 |
[Conservative therapy of patients with stable coronary heart disease].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Combined Modality Therapy; Coronary Disease; Drug Incompatibility; Enzyme Inhibitors; Heart Failure; Heart Rate; Humans; Life Style; Myocardial Infarction; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2012 |
The year in non-ST-segment elevation acute coronary syndrome.
Topics: Acetanilides; Acute Disease; Age Factors; Aged; Biomarkers; Bone Morphogenetic Proteins; Cardiac Catheterization; Cardiology; Coronary Disease; Electrocardiography; Enzyme Inhibitors; Female; Fibrinolytic Agents; Glucose Metabolism Disorders; Growth Differentiation Factor 15; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Piperazines; Practice Guidelines as Topic; Quality Assurance, Health Care; Ranolazine; Risk Assessment; Sex Factors | 2007 |
Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
Topics: Acetanilides; Carnitine; Clinical Trials as Topic; Coenzymes; Coronary Disease; Enzyme Inhibitors; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Superoxide Dismutase; Trimetazidine; Ubiquinone; Vasodilator Agents | 1995 |
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. As
Topics: Acetanilides; Angina Pectoris; Arrhythmias, Cardiac; Cardiology; Clinical Trials as Topic; Comorbidity; Coronary Disease; Defibrillators, Implantable; Depressive Disorder; Electric Countershock; Female; Heart Failure; Humans; Male; Nicorandil; Piperazines; Ranolazine; Sensitivity and Specificity | 2002 |
3 trial(s) available for ranolazine and Coronary Disease
| Article | Year |
|---|---|
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Topics: Administration, Oral; Angina Pectoris; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Hemodynamics; Humans; Magnetic Resonance Angiography; Male; Medication Adherence; Microvessels; Middle Aged; Myocardial Ischemia; Quality of Life; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2016 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Nitroglycerin; Piperazines; Ranolazine; Treatment Outcome; Vasodilator Agents | 2006 |
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
Topics: Acetanilides; Acute Disease; Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Diabetic Angiopathies; Electrocardiography; Electrophysiology; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Placebos; Ranolazine; Tachycardia; Thrombolytic Therapy | 2007 |
11 other study(ies) available for ranolazine and Coronary Disease
| Article | Year |
|---|---|
Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Topics: Aged; Angina, Stable; Cardiovascular Agents; Coronary Disease; Female; Humans; Male; Microcirculation; Middle Aged; Pilot Projects; Ranolazine; Treatment Outcome | 2017 |
Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Coronary Disease; Diabetes Mellitus, Type 2; Exercise Test; Female; Follow-Up Studies; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Pilot Projects; Ranolazine | 2016 |
The editor's roundtable: role of percutaneous coronary intervention and drug-eluting stents in patients with stable coronary heart disease.
Topics: Acetanilides; Acute Coronary Syndrome; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antithrombins; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Cost-Benefit Analysis; Diabetes Mellitus; Drug-Eluting Stents; Enzyme Inhibitors; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Medical History Taking; Medication Adherence; Multidetector Computed Tomography; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radionuclide Imaging; Ranolazine; Risk Factors; Troponin | 2011 |
New options help angina patients live more active lives. Treating the underlying disease may help you live longer, too.
Topics: Acetanilides; Angina Pectoris; Cardiotonic Agents; Coronary Disease; Counterpulsation; Female; Humans; Male; Piperazines; Ranolazine | 2007 |
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Topics: Acetanilides; Acute Coronary Syndrome; Acute Disease; Angina Pectoris; Cardiovascular Agents; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine; Recurrence; Sex Factors; Thrombolytic Therapy | 2008 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Acetanilides; Citric Acid Cycle; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme Inhibitors; Epoxy Compounds; Humans; Insulin Resistance; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2008 |
Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Topics: Acetanilides; Aged; Alanine; Angina Pectoris; Blood Pressure; Citric Acid; Coronary Circulation; Coronary Disease; Enzyme Inhibitors; Fatty Acids; Glucose; Glutamic Acid; Heart Rate; Humans; Lactic Acid; Male; Middle Aged; Myocardium; Piperazines; Ranolazine | 1997 |
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
Topics: Acetanilides; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Disease Models, Animal; Fatty Acids; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Troponin T | 2001 |
Cardiovascular news.
Topics: Acetanilides; Angina, Unstable; Anti-Arrhythmia Agents; Calcium Channel Blockers; Coronary Disease; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Fondaparinux; Humans; Hydantoins; Imidazoles; Imidazolidines; Multicenter Studies as Topic; Myocardial Infarction; Nicorandil; Piperazines; Polysaccharides; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2001 |
Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
Topics: Acetanilides; Angina Pectoris; Animals; Blood Pressure; Coronary Disease; Electrocardiography; Exercise Test; Heart Rate; Nitroglycerin; Piperazines; Ranolazine; Single-Blind Method | 1990 |
Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion.
Topics: Acetanilides; Animals; Cardiovascular Agents; Coronary Disease; Creatine Kinase; L-Lactate Dehydrogenase; Male; Myocardial Reperfusion; Myocardium; Papio; Piperazines; Ranolazine | 1990 |